亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma

阿霉素 医学 软组织肉瘤 肉瘤 临床研究阶段 肿瘤科 药理学 临床试验 化疗 内科学 病理
作者
Ian Judson,John Radford,Martin Harris,Jean‐Yves Blay,Q. van Hoesel,Axel Le Cesne,A.T. van Oosterom,M. Clemons,Claus Kamby,C. Hermans,J Whittaker,Eugenio Donato Di Paola,Jaco J. Verweij,Søren Nielsen
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:37 (7): 870-877 被引量:385
标识
DOI:10.1016/s0959-8049(01)00050-8
摘要

Abstract

CAELYX®/DOXIL®, pegylated liposomal doxorubicin, has shown antitumour activity and reduced toxicity compared with standard doxorubicin in other tumour types. In this prospective randomised trial, 94 eligible patients with advanced soft-tissue sarcoma (STS) were treated, 50 with CAELYX® (50 mg/m2 by a 1 h intravenous (i.v.) infusion every 4 weeks) and 44 with doxorubicin (75 mg/m2 by an i.v. bolus every 3 weeks). Histological subtypes were evenly matched, 33% were leiomyosarcoma (CAELYX®: 18; doxorubicin: 13). Primary disease sites were well matched. CAELYX® was significantly less myelosuppressive, only 3 (6%) patients had grade 3 and 4 neutropenia, versus 33 (77%) on doxorubicin; febrile neutropenia occurred in 7 (16%) patients given doxorubicin, but only 1 (2%) given CAELYX®. 37 (86%) patients on doxorubicin had grade 2–3 alopecia, but only 3 (6%) on CAELYX®, and the major toxicity with CAELYX® was to the skin. Palmar-plantar erythrodysesthesia with CAELYX® was grade 1: 4 (8%) patients, grade 2: 11 (22%) patients, grade 3: 9 (18%) patients and grade 4: 1 (2%) patient. Other non-haematological grade 3 and 4 toxicities were rare. Confirmed responses were observed with both agents: CAELYX®: complete response (CR) 1 (uterine), partial response (PR) 4 (response rate (RR) 10%); and doxorubicin: CR 1, PR 3 (RR of 9%); with the best response being stable disease (NC) in 16 and 18 patients, respectively. The reason for the low response rate is unknown, but it may be due partly to a high proportion of gastrointestinal stromal tumours. In conclusion, CAELYX® has equivalent activity to doxorubicin in STS with an improved toxicity profile and should be considered for further investigation in combination with other agents such as ifosfamide.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
2秒前
mmyhn发布了新的文献求助10
3秒前
zzzyyyy完成签到 ,获得积分10
3秒前
nickkk发布了新的文献求助10
7秒前
17秒前
星辰完成签到,获得积分10
19秒前
19秒前
冷傲的汉堡完成签到,获得积分10
21秒前
mmyhn发布了新的文献求助10
25秒前
27秒前
大模型的应助被邋遢大王采纳,获得10
27秒前
28秒前
小马甲的应助被废柴采纳,获得10
28秒前
zm18982426205完成签到 ,获得积分10
29秒前
FIGGIEKIO发布了新的文献求助10
31秒前
fanqie完成签到,获得积分10
32秒前
英姑的应助被188采纳,获得10
33秒前
33秒前
33秒前
spolo完成签到,获得积分10
39秒前
lan完成签到 ,获得积分10
41秒前
DaTao123完成签到,获得积分10
42秒前
无奈的琦完成签到,获得积分10
43秒前
nav完成签到 ,获得积分10
49秒前
朴实的懿轩完成签到,获得积分10
51秒前
哞的一声学习去了完成签到,获得积分10
55秒前
57秒前
赘婿的应助被zyyyyyy采纳,获得10
59秒前
Yu发布了新的文献求助10
59秒前
铃木完成签到,获得积分10
1分钟前
1分钟前
无花果的应助被想活在梦里采纳,获得10
1分钟前
1分钟前
清秀的落雁完成签到,获得积分10
1分钟前
秋风的应助被科研通管家采纳,获得10
1分钟前
1分钟前
zyyyyyy发布了新的文献求助10
1分钟前
烟花的应助被周开心采纳,获得10
1分钟前
岚仙完成签到,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8195004
求助须知:如何正确求助?哪些是违规求助? 9580729
关于积分的说明 21872554
捐赠科研通 7794720
什么是DOI,文献DOI怎么找? 3437836
关于科研通互助平台的介绍 2561159
邀请新用户注册赠送积分活动 2484541